TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES
申请人:MERCK SHARP & DOHME CORP.
公开号:US20140213571A1
公开(公告)日:2014-07-31
The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
[EN] PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS<br/>[FR] PYRROLOPYRIMIDINE AMINES EN TANT QU'INHIBITEURS DU COMPLÉMENT
申请人:BIOCRYST PHARM INC
公开号:WO2021202977A1
公开(公告)日:2021-10-07
Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
[EN] TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES TÉTRACYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION POUR LE TRAITEMENT DE MALADIES VIRALES
申请人:MERCK SHARP & DOHME
公开号:WO2013033971A1
公开(公告)日:2013-03-14
The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
申请人:McComas Casey C.
公开号:US09265773B2
公开(公告)日:2016-02-23
The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.